The activation of AR represses ER-regulated cell cycle genes and upregulates AR target genes which include tumour suppressors [27], and this supports the rationale for ongoing trials evaluating AR agonists in ER+ breast cancer (Table 3). This evidence concerns the gene AR and breast carcinoma.